Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  AUSTRALIAN SECURITIES EXCHANGE LIMITED  >  Cochlear Limited    COH   AU000000COH5

COCHLEAR LIMITED (COH)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Cochlear Limited : COH Jury Trial Verdict on USA Patent Infringement Case

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/24/2014 | 03:51am CET
ASX RELEASE 24th January 2014 COCHLEAR LIMITED: JURY TRIAL VERDICT ON USA PATENT INFRINGEMENT CASE

Cochlear Limited, Sydney, 24th January 2014 (ASX:COH) today announced that a jury verdict in the patent infringement lawsuit by the Alfred E. Mann Foundation for Scientific Research ("AMF") and Advanced Bionics LLC ("AB") has been reached.
A jury in the United States District Court in Los Angeles, California found direct, contributory and wilful, but not induced infringement against Cochlear Limited and its USA subsidiary Cochlear Americas and awarded damages of US$131.2 million against Cochlear.
No judgment has been entered based on the verdict as important issues still remain to be decided by the Judge. These decisions may negate some of the findings of the jury and could alter the damages awarded by the jury.
Cochlear believes the facts and the law do not support the jury's findings and will seek to overturn the verdict in post-trial motions with the District Court and, if necessary, through the appeals process.
This lawsuit was disclosed to ASX when it was filed in December 2007. The verdict relates to two (2) United States patents on testing systems and methods for a cochlear implant. The patents were exclusively licenced by AMF to AB which is a competitor to Cochlear.
One of the patents expired in September 2009 and the other expires in March 2014. As a result, the verdict and any following judgment entered against Cochlear will not disrupt Cochlear's business or customers in the United States.
As at the date of this announcement, Cochlear had not accrued any liability in its financial statements for this verdict. In addition, Cochlear has not yet determined the impact, if any, on its financial statements.
Cochlear's Chief Executive Officer and President Dr Chris Roberts said, "We strongly disagree with the jury verdict and will appeal any judgment entered against Cochlear by the Court".
Ends
Company contacts:
Dr Chris Roberts, CEO/President p: + 61 2 9428 6555
Neville Mitchell, CFO
p: + 61 2 9428 6555

Page 1 of 1

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on COCHLEAR LIMITED
01/07 COCHLEAR : Appendix 3Z - Chris Smith
2017 SENSORION : New Collaboration Focused on Drug, Cochlear Implant Combination for ..
2017 COCHLEAR : Patent Issued for Focused Stimulation in a Medical Stimulation Device..
2017 COCHLEAR : MILITARY $4,045 Federal Contract Awarded to Cochlear Americas
2017 SENSORION : and Cochlear Announce Collaboration to Study Combination Therapies f..
2017 SENSORION : and Cochlear Announce Strategic Collaboration for Patients with Coch..
2017 SENSORION : and Cochlear Announce Collaboration to Study Combination Therapies f..
2017 COCHLEAR : Patent Issued for Bone Anchor Fixture for a Medical Prosthesis (USPTO..
2017 COCHLEAR : Appendix 3Y - Chris Smith
2017 COCHLEAR : Patent Issued for Inductive Signal Transfer in an Implantable Medical..
More news
News from SeekingAlpha
2017 Apple and Cochlear announce Sound Processor for hearing implant
2017 WEEK IN REVIEW : BGI Genomics Completes $81-Million Chi-Next IPO
2016 How Do I Manage A Favorite Holding That's Now Overvalued?
2016 Smaller Medtechs In Charge Of Their Own Destiny
2016 The Psychology Of Investing
Financials ( AUD)
Sales 2018 1 389 M
EBIT 2018 350 M
Net income 2018 249 M
Debt 2018 65,0 M
Yield 2018 1,83%
P/E ratio 2018 38,32
P/E ratio 2019 33,24
EV / Sales 2018 6,97x
EV / Sales 2019 6,29x
Capitalization 9 622 M
Chart COCHLEAR LIMITED
Duration : Period :
Cochlear Limited Technical Analysis Chart | COH | AU000000COH5 | 4-Traders
Technical analysis trends COCHLEAR LIMITED
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 10
Average target price 145  AUD
Spread / Average Target -13%
EPS Revisions
Managers
NameTitle
Diggory William Howitt President, CEO & Executive Director
Roderick Holliday-Smith Chairman
Brent Cubis Chief Financial Officer
James F. Patrick Chief Scientist & Senior Vice President
Jan Janssen Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
COCHLEAR LIMITED-2.35%7 661
MEDTRONIC PLC5.66%115 480
STRYKER CORPORATION2.99%59 680
BECTON, DICKINSON AND COMPANY6.76%52 429
BAXTER INTERNATIONAL4.69%36 869
ESSILOR INTERNATIONAL-2.96%30 076